On Oct 31, major Wall Street analysts update their ratings for $Eli Lilly and Co (LLY.US)$, with price targets ranging from $975 to $1,100.
J.P. Morgan analyst Chris Schott maintains with a buy rating.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and adjusts the target price from $1,150 to $1,100.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,025 to $975.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $1,000.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating, and adjusts the target price from $1,033 to $1,029.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Eli Lilly's recent quarter showed variability in the performance of Mounjaro and Zepbound. However, it has been clarified that the fluctuations in Mounjaro and Zepbound were due to inventory dynamics rather than supply or demand issues. Despite a slight downturn in the third quarter, the outlook on Eli Lilly remains positive, with just a slight reduction in the forecasts for Mounjaro and Zepbound.
Following the Q3 report, there's a recognition that significant efforts will be necessary in Q4 due to the $1B shortfall in tirzepatide. This comes as channel inventories fluctuate markedly and the push for direct-to-consumer efforts is delayed until mid-quarter.
Here are the latest investment ratings and price targets for $Eli Lilly and Co (LLY.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$禮來 (LLY.US)$的評級，目標價介於975美元至1,100美元。
摩根大通分析師Chris Schott維持買入評級。
美銀證券分析師Alec Stranahan維持買入評級，並將目標價從1,150美元下調至1,100美元。
巴克萊銀行分析師Carter Gould維持買入評級，並將目標價從1,025美元下調至975美元。
富國集團分析師Mohit Bansal維持買入評級，維持目標價1,000美元。
儲億銀行分析師Srikripa Devarakonda維持買入評級，並將目標價從1,033美元下調至1,029美元。
此外，綜合報道，$禮來 (LLY.US)$近期主要分析師觀點如下：
Eli Lilly最近的季度表現顯示Mounjaro和Zepbound的表現存在差異。然而，已經澄清Mounjaro和Zepbound的波動是由庫存動態而不是供應或需求問題造成的。儘管第三季度有輕微下滑，但對Eli Lilly的前景仍然積極，只是對Mounjaro和Zepbound的預測略有降低。
在第三季度報告之後，人們意識到由於tirzepatide 10億美元的缺口，第四季度將需要進行重大努力。這是因爲渠道庫存大幅波動，直接面向消費者的推送計劃推遲到中季度。
以下爲今日5位分析師對$禮來 (LLY.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
